I tried HBOT- here’s what it did to my brain

Written by: Bryan Johnson

Published on: June 4, 2025

I tried HBOT- here’s what it did to my brain

Written by: Bryan Johnson

Published on: June 4, 2025

Hi Friends,

HBOT (Hyperbaric Oxygen Therapy) reduced a dementia-risk marker of mine by 28%.

Details:

+ pTAU217 just got FDA-cleared for early Alzheimer’s screening. It also has prognostic value for healthy brains.

+ The FDA just approved approved pTAU217/A𝛃42 ratio as the first blood test for the early detection of Alzheimer disease.

+ HBOT reduced my pTAU217 level by 28%.

+ A recent study also confirmed p-TAU217 as a marker of future dementia risk in healthy people.

0/ Phosphorylated tau protein (p-TAU217) is a disease marker that accumulates as tangles in the brains of individuals with Alzheimer's disease. Elevated concentrations of p-TAU217 can also be detected in the blood, higher concentrations predict faster disease progression.

1/ The FDA has just approved the marketing of Lumipulse G test, which uses pTAU217/A𝛃42 as the first blood test for early detection of Alzheimer disease in people over 55, showing symptoms for the disease.

2/ The marker has strong prognostic value in healthy people as well. A study found a simple p-Tau217 blood test to be equally predictive of future cognitive decline risk to much more complex brain imaging of Tau-tangles.

3/ Cognitively unimpaired individuals in the highest 25% of pTau217 levels demonstrated a 57% elevated risk of future cognitive decline. This is comparable to the 61% increased risk observed in those with the highest 25% of Tau accumulation in pertinent brain areas (a statistically insignificant difference).

The research proposes that p-TAU217 can serve as an initial screening tool in healthy individuals. Those with elevated blood p-Tau217 levels should then undergo brain imaging.

4/ HBOT reduced my blood p-TAU217 by 28% from 0.14 to 0.10 pg/mL.

0.15 pg/mL is considered the upper range of healthy.

Remember me,

Bryan